Infosys Q3 results on January 11

Monday, January 28, 2008, 14:34 [IST]

Bangalore, Dec 28: IT bellwether Infosys today said it would announce its results for the third quarter of the current fiscal on January 11.

The results would also be available on the company website, www.infosys.com. Infosys, in a release here, said its CEO and Managing Director S Gopalakrishnan, COO S D Shibulal, CFO V Balakrishnan and other members of the senior management would comment on the company's performance in a telecast by CNBC-TV18 as part of its 'boardroom' series direct from here at 1030 hrs.

UNI

Topics: infosys, net profit, q3

Other articles published on January 28, 2008

RBI rate cut ends sensex on a positive note

Monday, December 8, 2008,11:12 [IST]

Just in: Positive global cues, RBI rate cut move, and government's fiscal stimulus package aided market sentiment. Buying was seen in metal, realty, banking, capital goods, power and telecom stocks. The Sensex surged by 197.42 points closing at 9,162.11. NSE Nifty gained 69.60 points ending the day at 2784.4:06 PM 12/8/2008 Mumbai, Dec 8: Continuous buying in power, banking, metal, telecom, oil sector is keeping Sensex going. The Sensex rose 345 points to 9,310 and the Nifty went up 104 points.....

BSE Sensex tanked over 450 points

Wednesday, March 14, 2007,11:10 [IST]

Mumbai, Mar 14: The Sensex opened with sharp decline today by over 450 points in early trade on Bombay Stock Exchange following a setback on the global bourses.All Sensex stocks opened in red with heavy losses, as there was panic selling across the board. At 9.57 am, Sensex was down 453 points at 12,529 and Nifty was down 134 points at 3636. Major gainers in the opening trade were Rel Comm, Reliance, Satyam, ACC, Guj Ambuja, Infosys.OneIndia.....

Limitless Updates

Business News

News Archives

Biotechnology major Biocon forays into nephrology space

Friday, March 9, 2007,12:21 [IST]

Bangalore, Mar 09: Biotechnology major Biocon on Thursday forayed into the nephrology space with the launch of a portfolio of five renal therapy products for the domestic and global markets, which it said was cheaper compared to MNC drug prices. The new immunosuppressants for renal therapy are at least 35-40 per cent cheaper than the MNC drug prices in the similar product category, the company's Marketing Head Rakesh Bamzai said.The Bangalore-headquartered company's Chairman and Managing Director, Kiran Mazumdar-Shaw said.....